['acute coronary syndrome', 'percutaneous coronary intervention']
['ticagrelor, prasugrel, clopidogrel']

        Inclusion Criteria:

          -  Patients: age >18 yrs, < 75yrs

             -> 60 kg ( since March 2015 age >75 and < 60 kg eligible - but prasugrel reduced to
             5mg daily if randomized to personalized therapy arm)

          -  NSTEMI undergoing PCI will be eligible

        Exclusion Criteria:

        - Patients will be excluded if they have: i) a contra-indication for clopidogrel or
        prasugrel or ticagrelor (as per monograph), ii) have an intolerance to aspirin, iii) have
        absolute requirement for ticagrelor or prasugrel (e.g. stent thrombosis, allergic reaction
        to clopidogrel), iv) requirement for anti-coagulation treatment, v) a history of stroke,
        TIA or intracranial hemorrhage , vi) a platelet count < 100,000/μl, vii) a known bleeding
        diathesis, viii) hematocrit <30% or >52%, ix) severe liver dysfunction, x) renal
        insufficiency (creatinine clearance < 30ml/min), xi) adjuvant therapy with a glycoprotein
        IIbIIIa inhibitor.
      